4.6 Article

Methylation of HPV16 genome CpG sites is associated with cervix precancer and cancer

期刊

GYNECOLOGIC ONCOLOGY
卷 121, 期 1, 页码 59-63

出版社

ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.ygyno.2011.01.013

关键词

Cervical cancer; Human papillomavirus; Methylation

资金

  1. National Cancer Institute (RDB) [CA78527]
  2. Center for AIDS Research (CFAR)

向作者/读者索取更多资源

Objective. Invasive cervix cancer (ICC) is the second most common malignant tumor in women. Human papillomavirus 16 (HPV16) causes more than 50% of all ICC and is a major cause of cervix intraepithelial neoplasia (CIN). DNA methylation is a covalent modification predominantly occurring at CpG dinucleotides. Such epigenetic modifications are associated with changes in DNA-protein interactions and gene activation. This study examined the association of viral and host genomic methylation patterns and cervix neoplasia. Methods. Exfoliated cervical lavage samples positive for HPV16 from women with and without cytomorphic changes of infection (n = 46), CIN2 (n = 12), and CIN3+ (n = 27) were used to interrogate the methylation patterns of the HPV16 L1 gene and upstream regulatory region (URR), five host nuclear genes (TERT, RARB, DAPK1, MAL, and CADM1), and mitochondrial DNA (mtDNA). DNA isolated from exfoliated cervicovaginal cells was treated with bisulfite, specific regions of the viral and host genome were PCR amplified and CpG methylation was quantified using EpiTYPER and pyrosequencing. Results. Methylation at 14 of the tested CpG sites within the HPV16L1 region were significantly higher in CIN3+ compared to HPV16 genomes from women without CIN3+. In contrast, 2/16 CpG sites in HPV16 URR, 5/5 in TERT, 1/4 in DAPK1 and 1/3 mtDNA, and 2/5 in RARB were associated with increased methylation in CIN3+. Conclusions. These results indicate that increased methylation of CpG sites in the HPV16 L1 ORF is associated with CIN3+ and, thus, may constitute a potential biomarker for precancerous and cancerous cervix disease. (C) 2011 Elsevier Inc. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Health Care Sciences & Services

A SWIFT Method for Handing Off Obstetrical Patients on the Labor Floor

Jean-Ju Sheen, Laura Reimers, Shravya Govindappagari, Ivan M. Ngai, Diana Garretto, Roopali Donepudi, Pamela Tropper, Dena Golfman, Ashlesha K. Dayal, Peter S. Bernstein

Summary: This study aimed to improve patient handoffs on the labor floor by introducing the mnemonic SWIFT and formalized curricula for resident training, resulting in gradual improvements in completeness, clarity, and overall quality of handoff information.

JOURNAL OF PATIENT SAFETY (2021)

Article Oncology

The burden of selected cancers in the US: health behaviors and health care resource utilization

Laura Iadeluca, Jack Mardekian, Pratibha Chander, Markay Hopps, Geoffrey T. Makinson

CANCER MANAGEMENT AND RESEARCH (2017)

Article Oncology

Reliability, validity and important difference estimates for the NCCN-FACT Ovarian Symptom Index-18 (NFOSI-18)

Andrew Trigg, Masami Kelly, Laura Iadeluca, Jane Chang, Alejandro Moreno-Koehler, Andrew Yaworsky, Meaghan Krohe, Alex Rider, Joseph C. Cappelleri, David Cella, Kim Cocks

Summary: The study evaluated the psychometric performance of NFOSI-18 in advanced ovarian cancer, demonstrating acceptable reliability and construct validity of NFOSI-18 scores, along with provided guidance on clinically important differences.

FUTURE ONCOLOGY (2021)

Article Economics

The Cost-Effectiveness of Lorlatinib Versus Chemotherapy as a Second- or Third-Line Treatment in Anaplastic Lymphoma Kinase (ALK)-Positive Non-small-cell Lung Cancer in Sweden

Fredrik O. L. Nilsson, Sandra T. Asanin, Elizabeth T. Masters, Laura Iadeluca, Chrissy Almond, Miranda Cooper, Sarah Smith

Summary: The study suggests that second- or third-line+ lorlatinib is cost-effective for ALK-positive NSCLC patients compared to chemotherapy in Sweden, with ICERs below the country's cost-effectiveness threshold for high-severity diseases.

PHARMACOECONOMICS (2021)

Article Oncology

Real-World Outcomes Among Crizotinib-Treated Patients with ROS1-Positive Advanced Non-Small-Cell Lung Cancer: A Community Oncology-Based Observational Study

David Waterhouse, Laura Iadeluca, Sneha Sura, Keith Wilner, Birol Emir, Stan Krulewicz, Janet Espirito, Lauren Bartolome

Summary: The study found that crizotinib showed clinical benefit in patients with ROS1-positive advanced NSCLC in a US community oncology setting, but the patients were older with a higher proportion of smokers.

TARGETED ONCOLOGY (2022)

Article Oncology

Effectiveness of crizotinib versus entrectinib in ROS1-positive non-small-cell lung cancer using clinical and real-world data

Gabriel Tremblay, Michael Groff, Laura Iadeluca, Patrick Daniele, Keith Wilner, Robin Wiltshire, Lauren Bartolome, Tiziana Usari, Joseph C. Cappelleri, D. Ross Camidge

Summary: This study compares the clinical trial results of crizotinib and entrectinib in ROS1-positive non-small-cell lung cancer and compares the clinical trial data of crizotinib with real-world outcomes. The study finds that crizotinib and entrectinib have comparable efficacy in treating ROS1-positive non-small-cell lung cancer.

FUTURE ONCOLOGY (2022)

Article Economics

Matching-Adjusted Indirect Comparisons of Lorlatinib Versus Chemotherapy for Patients With Second-Line or Later Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer

Sarah Smith, Fernando Albuquerque de Almeida, Monica Ines, Laura Iadeluca, Miranda Cooper

Summary: This study compared the efficacy of lorlatinib and chemotherapy for patients with advanced ALK-positive non-small cell lung cancer. Lorlatinib showed a significant improvement in progression-free survival compared to chemotherapy. Limited evidence suggested that lorlatinib also improved overall survival compared to systemic therapy.

VALUE IN HEALTH (2023)

Article Oncology

Patient-reported outcomes from the randomized phase 3 CROWN study of first-line lorlatinib versus crizotinib in advanced ALK-positive non-small cell lung cancer

Julien Mazieres, Laura Iadeluca, Alice T. Shaw, Benjamin J. Solomon, Todd M. Bauer, Filippo de Marinis, Enriqueta Felip, Yasushi Goto, Dong-Wan Kim, Tony Mok, Arlene Reisman, Holger Thurm, Anna M. Polli, Geoffrey Liu

Summary: This study presents detailed patient-reported outcome data from a phase 3 study comparing lorlatinib with crizotinib in previously untreated ALK-positive advanced NSCLC patients. The results show that both drugs improved quality of life, functioning, and symptom scores during treatment. Lorlatinib showed better improvements in several symptoms, while crizotinib performed better in cognitive functioning.

LUNG CANCER (2022)

Article Critical Care Medicine

Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study

Benjamin J. Solomon, Todd M. Bauer, Tony S. K. Mok, Geoffrey Liu, Julien Mazieres, Filippo de Marinis, Yasushi Goto, Dong-Wan Kim, Yi-Long Wu, Jacek Jassem, Froylan Lopez Lopez, Ross A. Soo, Alice T. Shaw, Anna Polli, Rossella Messina, Laura Iadeluca, Francesca Toffalorio, Enriqueta Felip

Summary: After 3 years of follow-up, lorlatinib showed durable benefit over crizotinib in treatment-naive ALK-positive non-small-cell lung cancer patients, indicating the potential use of lorlatinib as a first-line treatment option.

LANCET RESPIRATORY MEDICINE (2023)

Article Oncology

Real-world study of next-generation sequencing diagnostic biomarker testing for patients with lung cancer in Japan

Toshiaki Takahashi, Makoto Nishio, Kazumi Nishino, Yasumasa Yoshiki, Naoko Shiraiwa, Birol Emir, Laura Iadeluca, Yasushi Yatabe, Kazuto Nishio

Summary: Our study found that sequential biomarker testing may result in longer time to treatment compared to simultaneous single biomarker testing. The Oncomine Dx target test (ODxTT), a next-generation sequencing-based multiplex biomarker panel test, has been approved in Japan and is expected to improve time to treatment. This retrospective observational study analyzed reimbursement data for lung cancer patients in Japan and showed that the use of ODxTT increased over time and contributed to a shorter time to treatment compared to single biomarker tests.

CANCER SCIENCE (2023)

Article Economics

Cost-Effectiveness of Lorlatinib in First-Line Treatment of Adult Patients with Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small-Cell Lung Cancer in Sweden

Jaesh Naik, Norma Beavers, Fredrik O. L. Nilsson, Laura Iadeluca, Chrissy Lowry

Summary: This study investigated the cost-effectiveness of lorlatinib as a first-line treatment for ALK-positive NSCLC in Sweden. The results showed that lorlatinib was a cost-effective option compared to crizotinib, alectinib, and brigatinib.

APPLIED HEALTH ECONOMICS AND HEALTH POLICY (2023)

Article Oncology

Benign breast disease and changes in mammographic breast density

Laura L. Reimers, Mandy Goldberg, Parisa Tehranifar, Karin B. Michels, Barbara A. Cohn, Julie D. Flom, Ying Wei, Piera Cirillo, Mary Beth Terry

Summary: This study found that women with self-reported BBD had higher mammographic breast density than women without BBD, particularly in women diagnosed with BBD before their first birth.

BREAST CANCER RESEARCH (2021)

Article Immunology

Racial differences in human papilloma virus types amongst United States women with HIV and cervical precancer

Marla J. Keller, Robert D. Burk, L. Stewart Massad, Isam-Eldin Eltoum, Nancy A. Hessol, Kathryn Anastos, Xianhong Xie, Howard Minkoff, Xiaonan Xue, Laura L. Reimers, Mark Kuniholm, Gypsyamber D'Souza, Christine Colie, Bradley Aouizerat, Joel M. Palefsky, Howard D. Strickler

Article Health Care Sciences & Services

The burden of family caregiving in the United States: work productivity, health care resource utilization, and mental health among employed adults

Markay Hopps, Laura Iadeluca, Margaret McDonald, Geoffrey T. Makinson

JOURNAL OF MULTIDISCIPLINARY HEALTHCARE (2017)

Article Oncology

Molecular landscape of ERBB2/HER2 gene amplification among patients with gynecologic malignancies; clinical implications and future directions

Dimitrios Nasioudis, Stefan Gysler, Nawar Latif, Lory Cory, Robert L. Giuntoli II, Sarah H. Kim, Fiona Simpkins, Lainie Martin, Emily M. Ko

Summary: The prevalence of ERBB2 gene amplification was investigated among patients with gynecologic malignancies. The study found that ERBB2 amplification is frequently encountered in uterine serous carcinoma and mucinous ovarian carcinoma, but less common in endometrioid endometrial carcinoma.

GYNECOLOGIC ONCOLOGY (2024)